{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:32:46Z","timestamp":1754145166138,"version":"3.41.2"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,16]]},"DOI":"10.7759\/cureus.88102","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:15:55Z","timestamp":1752689755000},"source":"Crossref","is-referenced-by-count":0,"title":["Fragmented Chemotherapy of Plasmablastic Lymphoma in an Immunocompromised Patient"],"prefix":"10.7759","author":[{"given":"Sabrina E","family":"Chin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen A","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandelise N","family":"Laudat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Santoscoy-Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Fonarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian","family":"Casadesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse HJ","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al.. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997, 89:1413-20. 10.1182\/blood.v89.4.1413","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27376","article-title":"Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Ramirez-Gamero A","year":"2024","unstructured":"Ramirez-Gamero A, Mart\u00ednez-Cordero H, Beltr\u00e1n BE, Florindez J, Malpica L, Castillo JJ. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024, 99:1586-94. 10.1002\/ajh.27376","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1387912","article-title":"Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base","volume":"59","author":"Qunaj L","year":"2018","unstructured":"Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018, 59:1375-83. 10.1080\/10428194.2017.1387912","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.015","article-title":"Plasmablastic lymphoma. A state-of-the-art review: part 2-focus on therapy","volume":"16","author":"Bibas M","year":"2024","unstructured":"Bibas M. Plasmablastic lymphoma. A state-of-the-art review: part 2-focus on therapy. Mediterr J Hematol Infect Dis. 2024, 16:e2024015. 10.4084\/MJHID.2024.015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref5","article-title":"Plasmablastic lymphoma","author":"Bhatt R","year":"2025","unstructured":"Bhatt R, Naha K, Desai DS. Plasmablastic lymphoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.007","article-title":"Plasmablastic lymphoma. A state-of-the-art review: part 1-epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors, and special populations","volume":"16","author":"Bibas M","year":"2024","unstructured":"Bibas M. Plasmablastic lymphoma. A state-of-the-art review: part 1-epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors, and special populations. Mediterr J Hematol Infect Dis. 2024, 16:e2024007. 10.4084\/MJHID.2024.007","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S142814","article-title":"Plasmablastic lymphoma: current perspectives","volume":"8","author":"Lopez A","year":"2018","unstructured":"Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018, 8:63-70. 10.2147\/BLCTT.S142814","journal-title":"Blood Lymphat Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo J","year":"2008","unstructured":"Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008, 83:804-9. 10.1002\/ajh.21250","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo JJ","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F, et al.. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019, 184:679-82. 10.1111\/bjh.15156","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog E","year":"2017","unstructured":"Tchernonog E, Faurie P, Coppo P, et al.. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017, 28:843-8. 10.1093\/annonc\/mdw684","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25955","article-title":"Survival analysis in treated plasmablastic lymphoma patients: a population-based study","volume":"95","author":"Florindez JA","year":"2020","unstructured":"Florindez JA, Alderuccio JP, Reis IM, Lossos IS. Survival analysis in treated plasmablastic lymphoma patients: a population-based study. Am J Hematol. 2020, 95:1344-51. 10.1002\/ajh.25955","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.014","article-title":"Epidemiologic characteristics, treatment patterns, and survival analysis of plasmablastic lymphoma in the United States: a SEER and NCDB analysis","volume":"24","author":"Hansen AR","year":"2024","unstructured":"Hansen AR, Vardell VA, Fitzgerald LA. Epidemiologic characteristics, treatment patterns, and survival analysis of plasmablastic lymphoma in the United States: a SEER and NCDB analysis. Clin Lymphoma Myeloma Leuk. 2024, 24:e152-e160.e3. 10.1016\/j.clml.2023.12.014","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355784-fragmented-chemotherapy-of-plasmablastic-lymphoma-in-an-immunocompromised-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:15:56Z","timestamp":1752689756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355784-fragmented-chemotherapy-of-plasmablastic-lymphoma-in-an-immunocompromised-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.88102","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}